Spearman correlation coefficients and p values for the relationship between RAMRIS scores and clinical, laboratory and radiographic findings
| GO-BEFORE (methotrexate-naive) | GO-FORWARD (methotrexate inadequate response) | |||||
|---|---|---|---|---|---|---|
| Synovitis* | Bone oedema (osteitis) | Bone erosions | Synovitis* | Bone oedema (osteitis) | Bone erosions | |
| Baseline RAMRIS vs: | ||||||
| Baseline DAS28 | 0.40 (p<0.001) | 0.18 (p=0.002) | 0.21 (p<0.001) | 0.17 (p=0.021) | 0.00 (p=0.96) | −0.02 (p=0.741) |
| Baseline CRP | 0.36 (p<0.001) | 0.37 (p<0.001) | 0.30 (p<0.001) | 0.27 (p<0.001) | 0.21 (p=0.002) | 0.13 (p=0.065) |
| Baseline total vdH-S | 0.26 (p<0.001) | 0.49 (p<0.001) | 0.64 (p<0.001) | 0.28 (p<0.001) | 0.53 (p<0.001) | 0.77 (p<0.001) |
| Baseline vdH-S erosion score | – | – | 0.58 (p<0.001) | – | – | 0.73 (p<0.001) |
| Week 24 RAMRIS vs: | ||||||
| Week 24 DAS28 | 0.30 (p<0.001) | 0.22 (p<0.001) | 0.23 (p<0.001) | 0.15 (p=0.05) | 0.00 (p=0.96) | 0.01 (p=0.89) |
| Week 24 CRP | 0.24 (p<0.001) | 0.25 (p<0.001) | 0.23 (p<0.001) | 0.21 (p=0.009) | 0.02 (p=0.84) | −0.02 (p=0.83) |
| Weeks 24/28 total vdH-S | 0.25 (p<0.001) | 0.48 (p<0.001) | 0.65 (p<0.001) | 0.47 (p<0.001) | 0.54 (p<0.001) | 0.76 (p<0.001) |
| Weeks 24/28 vdH-S erosion score | – | – | 0.59 (p<0.001) | – | – | 0.71 (p<0.001) |
| RAMRIS ∆ to week 12 vs: | ||||||
| DAS28 ∆ to week 12 | 0.21 (p=0.001) | 0.17 (p=0.008) | 0.14 (p=0.028) | 0.14 (p=0.08) | 0.21 (p=0.004) | 0.01 (p=0.87) |
| DAS28 ∆ to week 24 | 0.21 (p=0.002) | 0.10 (p=0.14) | 0.08 (p=0.22) | 0.21 (p=0.008) | 0.18 (p=0.013) | 0.02 (p=0.83) |
| CRP %∆ to week 4 | −0.17 (p=0.010) | −0.13 (p=0.040) | −0.005 (p=0.94) | −0.23 (p=0.002) | −0.19 (p=0.007) | 0.06 (p=0.39) |
| CRP %∆ to week 12 | −0.21 (p=0.002) | −0.19 (p=0.002) | −0.05 (p=0.45) | −0.22 (p=0.005) | −0.20 (p=0.006) | −0.04 (p=0.54) |
| Total vdH-S ∆ to weeks 24/28 | 0.08 (p=0.22) | 0.14 (p=0.033) | 0.05 (p=0.48) | 0.16 (p=0.07) | 0.10 (p=0.23) | −0.18 (p=0.027) |
| vdH-S erosion score ∆ to weeks 24/28 | – | – | 0.03 (p=0.59) | – | – | −0.15 (p=0.07) |
| RAMRIS ∆ to week 24 vs: | ||||||
| DAS28 ∆ to week 24 | 0.22 (p<0.001) | 0.13 (p=0.036) | 0.17 (p=0.006) | 0.36 (p<0.001) | 0.21 (p=0.008) | 0.10 (p=0.22) |
| CRP %∆ to week 24 | −0.20 (p=0.002) | −0.25 (p<0.001) | −0.06 (p=0.34) | −0.32 (p<0.001) | −0.22 (p=0.007) | −0.03 (p=0.69) |
| Total vdH-S ∆ to weeks 24/28 | 0.13 (p=0.06) | 0.07 (p=0.31) | 0.03 (p=0.63) | 0.12 (p=0.22) | 0.16 (p=0.09) | −0.06 (p=0.50) |
| vdH-S erosion score ∆ to weeks 24/28 | – | – | 0.07 (p=0.28) | – | – | −0.03 (p=0.75) |
Data are presented for all treatment groups combined.
↵* Several sites did not have the capability to obtain postgadolinium images of both the wrist and the metacarpophalangeal joints; therefore, RAMRIS synovitis scores are summarised and assessed for the subgroups of patients with both determinations.
CRP, C-reactive protein; DAS28, 28-joint disease activity score calculated using CRP; RAMRIS, rheumatoid arthritis MRI score; vdH-S, van der Heijde modified Sharp score.